Adaptive Biotechnologies (NASDAQ: ADPT) disclosed that its Chief Scientific Officer, Harlan S. Robins, completed sales totaling 24,233 shares of company stock across two trading days, March 2 and March 3, 2026. The transactions and related details appear in a Form 4 filing submitted to the Securities and Exchange Commission.
According to the filing, the sale on March 2 comprised 10,000 shares of Common Stock executed in multiple trades at prices that ranged from $15.57 to $15.88 per share. The following day, March 3, Robins sold an additional 14,233 shares in several transactions at prices between $16.50 and $16.55 per share. Collectively, those sales amounted to approximately $392,329.
The Form 4 notes that the dispositions were effected pursuant to a Rule 10b5-1 trading plan Robins adopted on August 11, 2025. After the March transactions, Robins is recorded as directly owning 1,155,291 shares of Adaptive Biotechnologies common stock.
Market context and valuation signals
The insider sales occurred while ADPT shares were trading at $16.44, a price that translated to a market capitalization of roughly $2.54 billion at the time of reporting. Over the trailing 12 months, the stock has returned 105%.
InvestingPro analysis referenced in the filing material indicates that ADPT may be trading above its Fair Value estimate, a valuation assessment flagged for investors considering the stock.
Recent financial performance and analyst moves
Adaptive Biotechnologies also reported fourth-quarter 2025 results that outpaced analyst expectations. The company posted an earnings per share (EPS) of -$0.09 for Q4 2025, representing a 50% positive surprise relative to the consensus forecast of -$0.18. Revenue for the quarter was $71.7 million, surpassing the anticipated $59.33 million by 20.85%.
Following the quarterly results, two sell-side firms adjusted their price targets. TD Cowen raised its target on Adaptive Biotechnologies to $21 while retaining its prior rating. BTIG lifted its price target to $22, citing strength in the company’s Minimal Residual Disease (MRD) business. The MRD segment expanded by 54% year-over-year in Q4 2025 and grew 46% for the full year, figures highlighted by the firm as a key growth driver.
Takeaway
The Form 4 filing documents a Rule 10b5-1 plan sale by a senior executive and updates current ownership levels following the disposition. Those sales occurred against a backdrop of stronger-than-expected quarterly results and notable MRD revenue growth, alongside analyst price-target increases and a valuation note from InvestingPro.